News and Comments

AGEN: IRRATIONAL REACTION AGAINST EXPECTED NEWS

  Thursday, March 20, 2014
 More...

PROSENSA: BACK INTO THE LIMELIGHT

  Tuesday, March 18, 2014

Prosensa Holding N.V. (RNA) might have good news that was made possible through insightful observation following past results that almost condemned the Dutch biopharmaceutical company’s compound drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD).  More...

JAKAFI DEVELOPED BY INCYTE MET THE PRIMARY ENDPOINTS FOR POLYCYTHEMIA VERA

  Friday, March 07, 2014

Incyte (INCY) announced results from pivotal Phase 3 trial of Jakafi (ruxolitinib) in polycythemia vera patients who are resistant to or intolerant of hydroxyurea. The results met the primary endpoints; achieving phlebotomy independence and reducing spleen size by 35 percent or more compared to best available therapy.  More...


Recent News_and_Comments


Archive


Tags